Expression of immune markers (PD-1, PD-L1 and CTLA-4 protein) was evaluated in 75 prospective cases of primary (Group I) and 25 cases of chemoreduced (Group II) enucleated retinoblastoma specimens by immunohistochemistry. This evidence concerns the gene CTLA4 and retinoblastoma.